Cambridge Academy of Therapeutic Sciences receives Wellcome funding to support translational research

Cambridge is one six institutions to receive funding to create partnerships with Wellcome. The others are the Universities of Bristol, Edinburgh and Manchester, Imperial College London, and Oxford University through the Mahidol Oxford Tropical Medicine Research Unit.

Researchers can face a number of barriers to taking the first step to translating their research – and often need more than financial support, including mentorship and regulatory advice, say Wellcome. Making the transition between discovery science and translation easier is one of the core aims of Wellcome’s Innovation for Impact strategy.

Through its new translational partnerships, Wellcome says it will explore new ways of supporting transition and to share best practice. Support through the new partnerships will be primarily, but not exclusively, for Wellcome-supported scientists and will include a portfolio of activities, such as: developing seed funds, identifying mentors and entrepreneurs in residence; offering access to Wellcome’s network of advisers, experts and mentors; and providing introductions to potential partners to take promising advances forward.

"We want to make sure there’s every opportunity for the people and organisations we support to translate great scientific discoveries into innovations with broad, lasting impact," says Stephen Caddick, Director of Innovation at Wellcome.

Wellcome says it will continue to identify new partners in order to build a broad global network to help share and spread great ideas and practice in translation and innovation.

Professor Chris Abell, Pro-Vice Chancellor for Research at the University of Cambridge, says: “We are very grateful to Wellcome for its support, which will help us foster new and innovative approaches to important health questions. The funding will allow us to encourage unique and unexpected collaborations that bring in expertise from across the University, including from outside traditional biomedical disciplines.

“We expect, too, to capitalise on our position within the largest biotech cluster outside the United States, to stimulate new partnerships with industry. These collaborations will provide an important pipeline of ideas that we hope will ultimately translate to tangible patient benefits.”